Patent EA-005316-B1 (EA)
Title: Aryl fused azapolycyclic compounds
Inventor: BROOKS PAIGE ROANNE PALMER
IPC: A61P21/00
Filed: 2001-02-08
Abstract: 1. A compound selected from the group consisting of: 6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene or 7-dimethylamino-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-5,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2,4(8),9-trien-6-one; (+)-6-oxo-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-5-yl)-benzamide; (+)-6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (+)-5-oxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (+)-6-methyl-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-7-dimethylamino-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (+)-1-(10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone; (-)-5,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2,4(8),9-trien-6-one; (+)-6-oxo-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.0<4.7>]dodeca-2(7),3,5-trien-5-yl)-benzamide; (-)-6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (-)-5-oxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (-)-6-methyl-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-7-dimethylamino-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,8-triene; (-)-1-(10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone; or a pharmaceutically acceptable salt thereof. 2. A compound selected from the group consisting of: 5,8,14-triazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,7,9-tetraen-6-one; (+)-6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-7-methyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-7-propyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-7-butyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (+)-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (+)-7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2,4(8),6,9-tetraene; (+)-5,8,14-triazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,7,9-tetraen-6-one; (-)-6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-7-methyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-7-propyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-7-butyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,5,8-tetraene; (-)-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2(10),3,6,8-tetraene; (-)-7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0<2.10>.0<4.8>]pentadeca-2,4(8),6,9-tetraene; (-)-5,8,14-triazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,7,9-tetraen-6-one; and a pharmaceutically acceptable salt thereof. 3. A compound selected from the group consisting of: 4,5-bistrifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-4-methyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-4-nitro-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-4-amino-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-N<1>-[10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl]acetamide; (+)-4-chloro-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-3-(10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl)-5-methyl-1,2,4-oxadiazole; (+)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-ol; (+)-N<4>,N<4>-dimethyl-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-sulfonamide; (+)-4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-5-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (+)-4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-5-ethynyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (+)-5-chloro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (+)-4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (+)-4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (+)-4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-4-methyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (-)-4-nitro-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-4-amino-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (-)-N<1>-[10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl]acetamide; (-)-4-chloro-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-3-(10-azatricycio[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl)-5-methyl-1,2,4-oxadiazole; (-)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-ol; (-)-N<4>,N<4>-dimethyl-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-sulfonamide; (-)-4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (-)-5-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (-)-4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-5-ethynyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (-)-5-chloro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (-)-4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (-)-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene-4-carbonitrile; (-)-4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof. 4. A compound selected from the group consisting of: (+)-3-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-3-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (+)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl-cyanide; (+)-4-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-3-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; (-)-3-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-triene; (-)-10-azatricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trien-4-yl-cyanide; (-)-4-fluoro-10-aza-tricyclo[6.3.1.0<2.7>]dodeca-2(7),3,5-trine; and a pharmaceutically acceptable salt thereof. 5. A compound selected from the group consisting of: 5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 6-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 7-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 7-ethyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 8-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,7,9-tetraen-6-one; 6-chloro-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 6-methoxy-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 6-chloro-10-fluoro-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; 6-chloro-3-fluoro-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; (+)-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; (+)-6-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]3,5,7,9-pentaene; (+)-7-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; (+)-7-ethyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; (+)-8-methyl-5,14-diazatetracyclo[10.3.1.0<2.11>.0<4.9>]hexadeca-2(11),3,5,7,9-pentaene; +)-5,14-diazate